Beppu Asami, Miyaaki Hisamitsu, Miuma Satoshi, Sasaki Ryu, Haraguchi Masafumi, Fukusima Masanori, Nakao Yasuhiko, Tajima Kazuaki, Matsuo Satoshi, Akazawa Yuko, Okano Shinji, Nakao Kazuhiko
Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Department of Histology and Cell Biology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Med Mol Morphol. 2025 Jun 5. doi: 10.1007/s00795-025-00440-4.
This study aimed to investigate carcinogenesis-related fibrosis patterns in liver biopsy tissues from patients with metabolic dysfunction-associated steatotic liver disease (MASLD) by comprehensively measuring and quantifying various fibrosis patterns using artificial intelligence. Liver biopsy tissues from 13 patients with advanced fibrosis at MASLD diagnosis were subjected to collagen quantification and morphological and structural fiber characteristic evaluation using FibroNest (PharmaNest, Princeton, NJ, USA), which was described using up to seven quantitative fibrosis parameters (qFPs). The collagen-fibrosis composite score (FCS), morphometric-FCS, architecture-FCS, and phenotypic-FCS (Ph-FCS) were compared between patients with and without hepatocellular carcinoma (HCC). The collagen quantification alone could not discriminate between HCC and non-HCC cases. Regarding the individual qFPs of morphological fiber characteristics, the kurtosis and skewness of fiber twists were significantly lower in HCC cases than in non-HCC cases. In HCC cases, fiber width and density kurtosis tended to be larger, whereas fiber length kurtosis tended to be smaller than those in non-HCC cases. Ph-FCS could discriminate HCC from non-HCC at a threshold of 4.2, with 85% sensitivity and 100% specificity. A combination of fiber morphology and structural characteristics predicted HCC development with higher accuracy and might help define carcinogenic risk groups among patients with MASLD.
本研究旨在通过使用人工智能全面测量和量化各种纤维化模式,调查代谢功能障碍相关脂肪性肝病(MASLD)患者肝活检组织中与致癌作用相关的纤维化模式。对13例在MASLD诊断时已出现晚期纤维化的患者的肝活检组织,使用FibroNest(美国新泽西州普林斯顿的PharmaNest公司)进行胶原定量以及形态和结构纤维特征评估,该评估使用了多达七个定量纤维化参数(qFPs)。比较了有和没有肝细胞癌(HCC)的患者之间的胶原-纤维化综合评分(FCS)、形态计量FCS、结构FCS和表型FCS(Ph-FCS)。仅胶原定量无法区分HCC和非HCC病例。关于形态纤维特征的各个qFPs,HCC病例中纤维扭曲的峰度和偏度显著低于非HCC病例。在HCC病例中,纤维宽度和密度峰度往往更大,而纤维长度峰度往往小于非HCC病例。Ph-FCS在阈值为4.2时可区分HCC和非HCC,灵敏度为85%,特异性为100%。纤维形态和结构特征的组合能更准确地预测HCC的发生,可能有助于在MASLD患者中定义致癌风险组。